IMU Biosciences's $53M+: Decoding the Immune System at Scale
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
Bengaluru's FirstClub raised $55M Series B in June 2026, doubling its valuation to $255M by betting that quality — not just speed — wins quick commerce.
Stockholm AI startup Endra raised $50M Series A in June 2026 to automate design work for mechanical, electrical, and plumbing (MEP) consultants.
Alpha Edison participated in the Series C for Oxford Quantum Circuits in June 2026, as the LA firm is reported to be raising a new $340M fund.
Aippy, built by NADA AI, raised tens of millions at a $250M valuation in June 2026 to build the first AI-native game community — Asia's answer to AI entertainment.
Ex-Meta CTO Mike Schroepfer's Gigascale Capital closed its first institutional fund at $250M in June 2026 to back energy, materials, and grid infrastructure.